Aura Biosciences Inc (AURA) Price & Analysis

Compare

276 Followers

AURA Stock Chart & Stats

$5.41

-$0.11(-1.36%)

At close: Jan 08 4:00 PM EST

$5.41

-$0.11(-1.36%)

Day’s Range― - ―

52-Week Range$4.35 - $11.99

Previous CloseN/A

Volume82.15K

Average Volume (3M)302.40K

Market Cap

$352.84M

Enterprise Value$203.98M

Total Cash (Recent Filing)$177.31M

Total Debt (Recent Filing)$18.11M

Price to Earnings (P/E)―

Beta2.11

Next Earnings

Mar 31, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding62,119,873

10 Day Avg. Volume325,525

30 Day Avg. Volume302,397

Financial Highlights & Ratios

PEG Ratio0.50

Price to Book (P/B)2.69

Price to Sales (P/S)0.00

P/FCF Ratio-5.03

Enterprise Value/Market Cap0.58

Enterprise Value/Revenue164.77

Enterprise Value/Gross Profit-715.72

Enterprise Value/Ebitda-1.96

Forecast

1Y Price Target

$21.75

Price Target Upside302.03% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe Phase 3 CoMpass trial for bel-sar in early-stage choroidal melanoma is actively enrolling with over 240 patients pre-screened, indicating strong progress toward full enrollment by year-end.

Financial PositionAura reported $177.3 million in cash and cash equivalents, which they expect to provide runway into the first half of 2027, reflecting a strong financial position.

Intellectual PropertyRecent IP developments, including a new formulation patent with potential exclusivity to 2046, further strengthen Aura’s competitive positioning.

Bears Say

Investor SentimentThe short interest is 8.3% of the float, indicating a significant level of skepticism from some investors.

Aura Biosciences Inc News

Aura Biosciences Advances Bladder Cancer Treatment with AU-011 Study

Aura Biosciences Inc (($AURA)) announced an update on their ongoing clinical study. Aura Biosciences Inc. is conducting a...

12d ago

AURA

Aura Biosciences Advances Eye Cancer Treatment with Phase 2 Trial Update

Aura Biosciences Inc (($AURA)) announced an update on their ongoing clinical study. Aura Biosciences Inc. is conducting a...

12d ago

AURA

Aura Biosciences’ Phase 3 Trial: A Potential Game-Changer in Ocular Melanoma Treatment

Aura Biosciences Inc (($AURA)) announced an update on their ongoing clinical study. Aura Biosciences Inc (AURA) is conducting...

12d ago

AURA

Optimistic Buy Rating for Aura Biosciences Inc: Promising Pipeline, Strategic Positioning, and Strong Financials

Leerink Partners analyst Andrew Berens maintained a Buy rating on Aura Biosciences Inc on August 13 and set...

3M ago

AURA

Aura Biosciences Advances Clinical Trials and Strengthens Finances

Aura Biosciences Inc ( ($AURA) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

AURA

Aura Biosciences Inc: Promising Clinical Developments and Strong Financial Position Support Buy Rating

TD Cowen analyst Phil Nadeau has maintained their bullish stance on AURA stock, giving a Buy rating today....

3M ago

AURA

Aura Biosciences Inc’s Promising Clinical Advancements and Strategic Positioning Justify Buy Rating

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Aura Biosciences Inc today and set a...

3M ago

AURA

Positive Outlook on Aura Biosciences: Strategic Developments and Promising Trials Drive Buy Rating

In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Aura Biosciences Inc,...

3M ago

AURA

Aura Biosciences Reports Q2 Results and $75M Financing

Aura Biosciences Inc ( ($AURA) ) just unveiled an announcement. On August 13, 2025, Aura Biosciences reported its...

3M ago

AURA

Aura Biosciences reports Q2 EPS (47c) vs (41c) last year

“We continued to focus on execution in our clinical programs in the second quarter, including our ongoing global...

3M ago

AURA

3 ‘Strong Buy’ Russell 2000 Stocks with Triple-Digit Upside Potential

As the market continues to navigate economic uncertainty, investors are increasingly looking toward smaller companies with high growth...

4M ago

AURA

NUVB

Aura Biosciences assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Andres Maldonado assumed coverage of Aura Biosciences (AURA) with a Buy rating and $22 price...

5M ago

AURA

Aura Biosciences 11.7M share Spot Secondary priced at $4.90

Leerink and Evercore ISI acted as joint book running managers for the offering. Published first on TheFly –...

6M ago

AURA

Aura Biosciences announces common stock, warrant offering, no amount given

Aura Biosciences (AURA) announced the launch of an underwritten public offering of shares of its common stock and...

6M ago

AURA

AURA FAQ

What was Aura Biosciences Inc’s price range in the past 12 months?

Aura Biosciences Inc lowest stock price was $4.34 and its highest was $11.99 in the past 12 months.

What is Aura Biosciences Inc’s market cap?

Aura Biosciences Inc’s market cap is $352.84M.

When is Aura Biosciences Inc’s upcoming earnings report date?

Aura Biosciences Inc’s upcoming earnings report date is Mar 31, 2026 which is in 143 days.

How were Aura Biosciences Inc’s earnings last quarter?

Currently, no data Available

Is Aura Biosciences Inc overvalued?

According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aura Biosciences Inc pay dividends?

Aura Biosciences Inc does not currently pay dividends.

What is Aura Biosciences Inc’s EPS estimate?

Aura Biosciences Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aura Biosciences Inc have?

Aura Biosciences Inc has 62,119,873 shares outstanding.

What happened to Aura Biosciences Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Aura Biosciences Inc?

Currently, no hedge funds are holding shares in AURA

Aura Biosciences Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-55.39%

Trailing 12-Months

Asset Growth

-6.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aura Biosciences Inc

Aura Biosciences Inc (AURA) is a biotechnology company focused on developing novel therapies for the treatment of various cancers. The company's core product candidates are designed to selectively target and destroy cancer cells while minimizing damage to surrounding healthy tissues. Aura Biosciences is particularly known for its work in ocular oncology, including the development of proprietary virus-like drug conjugates that target ocular and other rare cancers.

Aura Biosciences Inc (AURA) Earnings & Revenues

Historic Earnings Reports

AURA Stock 12 Month Forecast

Average Price Target

$21.75

▲(302.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","14":"$14","19":"$19","24":"$24"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9,14,19,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.31,7.593846153846154,8.877692307692307,10.161538461538461,11.445384615384615,12.72923076923077,14.013076923076923,15.296923076923076,16.58076923076923,17.864615384615384,19.14846153846154,20.432307692307692,21.716153846153844,{"y":23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.31,7.497692307692308,8.685384615384615,9.873076923076923,11.060769230769232,12.248461538461537,13.436153846153847,14.623846153846156,15.811538461538461,16.99923076923077,18.186923076923076,19.374615384615385,20.562307692307694,{"y":21.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.31,7.363076923076923,8.416153846153847,9.46923076923077,10.522307692307692,11.575384615384616,12.62846153846154,13.681538461538462,14.734615384615385,15.787692307692307,16.840769230769233,17.893846153846155,18.946923076923078,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.86,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.58,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.31,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >